XML 30 R18.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Balance Sheet Components (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract] |
Schedule of Cash and Cash Equivalents | Cash and cash equivalents consisted of the following (in thousands):
|  | September 30, 2016 |  |  | December 31, 2015 |
Cash |  | $ | 92,620 |  |  | $ | 75,685 |
Money market funds |  |  | 105,663 |  |  |  | 77,639 |
Total cash and cash equivalents |  | $ | 198,283 |  |  | $ | 153,324 |
Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments | All investments are classified as available-for-sale. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale investments by major investments type are summarized in the tables below (in thousands):
|  | September 30, 2016 |
|  | Amortized Cost |  |  | Gross Unrealized Holding Gains |  |  | Gross Unrealized Holding Losses |  |  | Fair Value |
Corporate bonds |  | $ | 118,291 |  |  | $ | 547 |  |  | $ | (7 | ) |  | $ | 118,831 |
Bond and mutual funds |  |  | 23,049 |  |  |  | 152 |  |  |  | — |  |  |  | 23,201 |
Equity investments |  |  | 125 |  |  |  | 95 |  |  |  | — |  |  |  | 220 |
Total investments |  | $ | 141,465 |  |  | $ | 794 |  |  | $ | (7 | ) |  | $ | 142,252 |
|  | December 31, 2015 |
|  | Amortized Cost |  |  | Gross Unrealized Holding Gains |  |  | Gross Unrealized Holding Losses |  |  | Fair Value |
Corporate bonds |  | $ | 126,522 |  |  | $ | 54 |  |  | $ | (473 | ) |  | $ | 126,103 |
Certificate of deposits |  |  | 8,217 |  |  |  | — |  |  |  | (2 | ) |  |  | 8,215 |
Bond and mutual funds |  |  | 25,052 |  |  |  | — |  |  |  | — |  |  |  | 25,052 |
Equity investments |  |  | 126 |  |  |  | 71 |  |  |  | — |  |  |  | 197 |
Total investments |  | $ | 159,917 |  |  | $ | 125 |  |  | $ | (475 | ) |  | $ | 159,567 |
Schedule of Accrued Liabilities | Accrued liabilities consisted of the following (in thousands):
|  | September 30, 2016 |  |  | December 31, 2015 |
Preclinical and clinical trial accruals |  | $ | 30,746 |  |  | $ | 27,973 |
Payroll and related accruals |  |  | 12,304 |  |  |  | 13,535 |
Professional services |  |  | 1,730 |  |  |  | 1,662 |
Other |  |  | 6,968 |  |  |  | 4,762 |
Total accrued liabilities |  | $ | 51,748 |  |  | $ | 47,932 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accrued liabilities. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of cash and cash equivalents. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration